Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of intravitreal lampalizumab for geographic atrophy secondary to age-related macular degeneration
NL-OMON41786Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lampalizumab in age-related macular degeneration (AMD) (3 arms), sponsored by Roche. Primary endpoint: Geographic atrophy area at 1 year. Started Oct 2015; status: active, not recruiting.
02
Drugs
lampalizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON41786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41786.